re: one of these Cephalon valued the co at $4.85 two years ago with little revenues and not much profits, 20 US centers, no Australian reimburrsemeent, and early clinical trials. Now the co has 75 US centers , doubling last years revenues, highly profitable with high margins , New US plant built and coming on line, 4 new chemio drugs that work with Sir spheres synergistally, 4 major pharma collaborations, Australian reimbursement this quarter, and expanding indications for the product. THis is most definitely worth 9-11 to one of many bidders.
genentech inc., page-9
Add SRX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
19.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $80.64M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1000 | 21.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 19.0¢ | 1 | 1 |
View Market Depth
| Last trade - 16.12pm 19/07/2024 (20 minute delay) ? |
| SRX (ASX) Chart |
Day chart unavailable